<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04533022</url>
  </required_header>
  <id_info>
    <org_study_id>VP-C21-005</org_study_id>
    <secondary_id>2020-000822-24</secondary_id>
    <nct_id>NCT04533022</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF</brief_title>
  <official_title>A Phase 2, Multi-Centre, Open-Label, Single-Arm Trial Investigating the Safety, Efficacy and Pharmacokinetics of C21 in Subjects With Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vicore Pharma AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orphan Reach</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vicore Pharma AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a multi-centre, open-label, single-arm phase 2 trial investigating the safety,&#xD;
      efficacy and pharmacokinetics of C21 in subjects with idiopathic pulmonary fibrosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nature and frequency of adverse events occurring over the trial period</measure>
    <time_frame>Trial period of 36 weeks</time_frame>
    <description>Primary endpoint</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>C21</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C21</intervention_name>
    <description>C21 b.i.d.</description>
    <arm_group_label>C21</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent, consistent with ICH-GCP R2 and local laws, obtained before&#xD;
             the initiation of any trial related procedure&#xD;
&#xD;
          2. A diagnosis of IPF within 3 years prior to Visit 1, as per either&#xD;
             ATS/ERS/JRS/ATLAT/Fleischner guidelines&#xD;
&#xD;
          3. Age ≥40 years&#xD;
&#xD;
          4. FVC ≥60% predicted at Visit 1 (specifically for UK: FVC ≥80% predicted at Visit 1)&#xD;
&#xD;
          5. FEV1/FVC ratio ≥0.7 prebronchodilator at Visit 1&#xD;
&#xD;
          6. Oxygen saturation (SpO2) &gt;85% by pulse oximetry while breathing ambient air at rest at&#xD;
             Visit 1&#xD;
&#xD;
          7. High-resolution computed tomography (HRCT) within 36 months prior to Visit 1 with&#xD;
             central reading demonstrating either a or b, and c:&#xD;
&#xD;
             a. A pattern consistent with usual interstitial pneumonitis (UIP) according to&#xD;
             ATS/ERS/JRS/ALAT or Fleischner guidelines i. UIP ii. Probable UIP or b. A pattern&#xD;
             indeterminate for UIP according to either ATS/ERS/JRS/ALAT or Fleischner guidelines&#xD;
             and a historical biopsy consistent with IPF c. Extent of fibrosis &gt; extent of&#xD;
             emphysema&#xD;
&#xD;
          8. Fully vaccinated against COVID-19 prior to screening (Visit 1). Subjects are&#xD;
             considered fully vaccinated for COVID-19 ≥14 days after they have received vaccination&#xD;
             dose(s) according to local label&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous and concomitant use of nintedanib or pirfenidone&#xD;
&#xD;
          2. Smoking (including e-cigarettes) within 6 months prior to Visit 1&#xD;
&#xD;
          3. Body mass index (BMI) &gt;35 or &lt;18&#xD;
&#xD;
          4. IPF exacerbation within 3 months prior to Visit 1:&#xD;
&#xD;
               -  Acute worsening or development of dyspnoea typically &lt;1 month duration&#xD;
&#xD;
               -  Computed tomography with new bilateral ground-glass opacity and/or consolidation&#xD;
                  superimposed on a background pattern consistent with usual interstitial pneumonia&#xD;
                  pattern (if no previous computed tomography is available, the qualifier &quot;new&quot; can&#xD;
                  be dropped)&#xD;
&#xD;
               -  Deterioration not fully explained by cardiac failure or fluid overload&#xD;
&#xD;
          5. Concurrent serious medical condition with special attention to cardiac or ophthalmic&#xD;
             conditions (e.g. contraindications to cataract surgery) which in the opinion of the&#xD;
             investigator makes the subject inappropriate for this trial&#xD;
&#xD;
          6. Malignancy within the past 5 years with the exception of in situ removal of basal cell&#xD;
             carcinoma and cervical intraepithelial neoplasia grade I&#xD;
&#xD;
          7. Treatment with any of the medications listed below within 4 weeks prior to Visit 1:&#xD;
&#xD;
               -  Cytochrome p450 (CYP) 3A4 inducers (e.g. rifampicin, phenytoin, St. John's Wort)&#xD;
&#xD;
               -  CYP3A4 inhibitors (e.g. clarithromycin, ketoconazole, nefazodone, itraconazole,&#xD;
                  ritonavir)&#xD;
&#xD;
               -  Medicines that are substrates of CYP1A2, CYP3A4 or CYP2C9 with a narrow&#xD;
                  therapeutic range&#xD;
&#xD;
               -  Experimental drugs&#xD;
&#xD;
               -  Any systemic immunosuppressive therapies other than:&#xD;
&#xD;
               -  Inhaled corticosteroids which can be used throughout the trial period provided&#xD;
                  the dose is kept stable&#xD;
&#xD;
               -  Corticosteroids for the treatment of acute exacerbations&#xD;
&#xD;
               -  The continuation of stable doses of ≤15 mg daily doses of prednisolone&#xD;
&#xD;
          8. Treatment with any of the medications listed below within 2 weeks prior to Visit 1:&#xD;
&#xD;
               -  Proton pump inhibitors (PPI's) more than once daily&#xD;
&#xD;
               -  Histamine H2 receptor antagonists (H2RA's)&#xD;
&#xD;
               -  Breast cancer resistance protein sensitive substrates (e.g. sulphasalazine,&#xD;
                  rosuvastatin)&#xD;
&#xD;
          9. Any of the following findings at Visit 1:&#xD;
&#xD;
               -  Prolonged QTcF (QT interval with Fridericia's correction) (&gt;450 ms), cardiac&#xD;
                  arrhythmias or any clinically significant abnormalities in the resting ECG, as&#xD;
                  judged by the Investigator&#xD;
&#xD;
               -  Positive results for hepatitis B surface antigen (HBsAg), hepatitis C virus&#xD;
                  antibody (HCVAb) or human immunodeficiency virus 1+2 antigen/antibody (HIV 1+2&#xD;
                  Ag/Ab)&#xD;
&#xD;
               -  Positive serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of&#xD;
                  human chorionic gonadotropin)&#xD;
&#xD;
         10. Inability to generate lung function data at Visit 1 meeting the minimum standards of&#xD;
             the ATS/ERS 2005 guideline, as determined by central review&#xD;
&#xD;
         11. Clinically significant abnormal laboratory value at Visit 1 indicating a potential&#xD;
             risk for the subject if enrolled in the trial as evaluated by the investigator&#xD;
&#xD;
         12. Pregnant or breast-feeding female subjects&#xD;
&#xD;
         13. Female subjects of childbearing potential not willing to use contraceptive methods&#xD;
&#xD;
         14. Male subjects not willing to use contraceptive methods&#xD;
&#xD;
         15. Subjects not willing to adhere to dietary restrictions during the trial period&#xD;
&#xD;
         16. Participation in any other interventional trial during the trial period&#xD;
&#xD;
         17. Subjects known or suspected of not being able to comply with this trial protocol (e.g.&#xD;
             due to alcoholism, drug dependency or psychological disorder)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanna Porter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Respiratory Medicine, University College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mikkel Walmar, MSc</last_name>
    <phone>+45 41904422</phone>
    <email>mikkel.walmar@vicorepharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rohit Batta, MD</last_name>
    <phone>+44 (0) 7950670515</phone>
    <email>rohit.batta@vicorepharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AMCMET Medical College and Sheth LG General Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380008</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay Tripathi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unity Hospital</name>
      <address>
        <city>Surat</city>
        <state>Gujarat</state>
        <zip>395010</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dipak Viradia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Bhatia Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400007</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sujeet Rajan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grant Government Medical Collage and Sir J.J. Group of Hospitals</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400008</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priti Meshram</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>N. K. P. Salve Institute of Medical Sciences &amp; Research Centre and Lata Mangeshkar Hospital</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440019</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anil Sontakke</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ace Hospital &amp; Research Center</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Himanshu Pophale</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oyster &amp; Pearl Hospitals</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411005</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashish Goyal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hindusthan Hospital</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamilnadu</state>
        <zip>641028</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Srikanth Krishnamurthy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jawaharlal Nehru Medical College - Aligarh Muslim University</name>
      <address>
        <city>Alīgarh</city>
        <state>Uttar Pradesh</state>
        <zip>202002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuber Ahmad</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midland Healthcare and Research Centre</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bhanu P Singh</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kazan State Medical University</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Vizel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moscow State Medical University</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evgeniy Shmelev</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Petersburg Pavlov State Medical University</name>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhail Ilkovich</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital for Emergency Medical Care n.a. N.V. Solovyev</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Yakusevich</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MNCE City Clinical Hospital</name>
      <address>
        <city>Kharkiv</city>
        <zip>61124</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Blazhko</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lviv National Medical University</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentyna Chopyak</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odessa Regional Hospital</name>
      <address>
        <city>Odessa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oleksandr Smolianyy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Private Small Scale Enterprise Medical Center 'PULSE'</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21001</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuriy Mostovoy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Porter, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joanne Porter, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medicines Evaluation Unit</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nazia Chaudhuri</last_name>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic Pulmonary Fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

